➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Moodys
Mallinckrodt
Medtronic
AstraZeneca

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 7,067,648

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,067,648
Title:Regulatory sequences of the mouse villin gene--use in transgenesis
Abstract: The invention relates to regulatory sequences of the mouse villin gene that efficiently drive transgenic expression in immature and differentiated epithelial cells of the intestine and uro-genital tracts. The invention also relates to recombinant constructs comprising said regulatory sequences, for the control of the targeted expression of determined nucleic acid sequences so-called (heterologous sequences or also transgenes), in cells or tissues originating from the intestinal mucosa. A further object of the invention is to provide cells, tissues or organisms including animals, expressing said determined nucleic acid sequences in a targeted manner.
Inventor(s): Pinto; Daniel (Bagnolet, FR), Robine; Sylvie (Vanves, FR), Jaisser; Frederic (Malakoff, FR), Louvard; Daniel (Sceaux, FR)
Assignee: Institut Curie (FR) Centre National de la Recherche and Scientifique (FR)
Application Number:09/877,935
Patent Claims:see list of patent claims

Details for Patent 7,067,648

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Institut Curie (FR) Centre National de la Recherche and Scientifique (FR) 2018-12-09 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Institut Curie (FR) Centre National de la Recherche and Scientifique (FR) 2018-12-09 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Institut Curie (FR) Centre National de la Recherche and Scientifique (FR) 2018-12-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Merck
Dow
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.